AMLX · Program file
avexitide
Amylyx Pharmaceuticals, Inc. (AMLX)
When did Amylyx Pharmaceuticals, Inc. say avexitide results would come?
On , Amylyx Pharmaceuticals, Inc. wrote in its SEC Form 10-Q: “We continue to expect to announce topline data in the third quarter of 2026, and, if approved, a commercial launch in 2027.” (Source)
Window ended 2026-09-30 · no results filing found as of 2026-10-11 · company’s wording: “third quarter of 2026”
Last checked: .
Watch this program: confirm your email to start one daily alert digest.
Program file
- Name as filed
- avexitide
- Other names in filings
- None listed
- Indication in the filing
- post-bariatric hypoglycemia (PBH) following Roux-en-Y gastric bypass (RYGB) surgery
- Trials named in the same filing
- NCT06747468
- Latest timing wording
- “We continue to expect to announce topline data in the third quarter of 2026, and, if approved, a commercial launch in 2027.”
- Source
- 10-Q · filed · SEC accepted · accession 0001193125-26-336682 · SEC original
- Last checked
- Correction
- : The SEC acceptance time shown for avexitide (AMLX) on its program page was 2026-08-06T15:04:23Z, four hours later than the time in SEC's own header for the filing (10-Q, accession 0001193125-26-336682, filed 2026-08-06). It was shown from 2026-10-12, when the program file was published. Replaced with the header time, 2026-08-06T11:04:23Z. Checked on 2026-10-12 by reading the filing's SEC header; the other 14 program files matched. The review label is unchanged: the acceptance time is metadata, and the quoted wording and its source are unchanged. Earlier daily hashes and records are not changed; this correction is a new record. SEC header · Evidence · All corrections
Program AMLX-avexitide.